Headquarters: San Clemente, California, United States
Trade prices
Volume:
Market Cap:2.26B
Prev closed:
Open:
High:
Low:
52 week low:
52 week high:
Dividends:No Dividends
Next ER:August 2, 2023
Top Stories (GKOS)
Company Profile
We are an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. We have pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. We launched the iStent®, our first MIGS device, in the United States in July 2012 and launched our next-generation iStent inject® device in the United States in September 2018. We are leveraging our platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
Talk about Glaukos Corp below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Want to know the strategies of successful swing trading? This friendly guide covers the ins and outs of this risky but profitable investing approach, explaining all the basics in plain English. You'll see how to use the two investment approaches - technical and fundamental analysis - to indentify promising securities in strongly trending markets. In addition, this guide covers how to calculate investment returns and, most important, how to manage your portfolio's risk.
Take advantage of price swings in strongly trending securities and pump up your portfolio!
